Combined endocrine treatment with a CDK4/6 inhibitor is now the standard of care in either first- or second-line treatment of metastatic ER+ breast cancer (Wardell et al., 2015a; Dean et al., 2010; Yang et al., 2017). Here, CDK4 is linked to breast carcinoma.